Clinical trials: SCCHN
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Patients With Non-curable Head and Neck Cancer
The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer
- Trial name
- NCT00382031
- Testing
- Zalutumumab, Control
- Where
- 82 sites in Belgium, Brazil and 10 more
- Volunteers
- 286 people
- Sponsor
- Genmab
Squamous Cell Carcinoma of the Head and Neck
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than…
- Trial name
- NCT03349710
- Testing
- Nivolumab, Cetuximab, Cisplatin
- Where
- 55 sites in United States, France and 8 more
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms, Head and Neck
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with head and neck cancer following surgery.
- Trial name
- NCT00424255
- Testing
- Lapatinib, Chemoradiation
- Where
- 117 sites in United States, Argentina and 20 more
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body.
- Trial name
- NCT03085719
- Testing
- Pembrolizumab, Radiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Squamous Cell, Head and Neck Cancer
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced…
- Trial name
- NCT02994069
- Testing
- Cisplatin, XRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Susanne Arnold
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Squamous Cell Cancer
Study of Sorafenib/Cetuximab in Head and Neck Cancer
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00815295
- Testing
- Sorafenib, Cetuximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
- Trial name
- NCT02207530
- Testing
- MEDI4736
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Head and Neck Cancer
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00891904
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Squamous Cell Carcinoma of the Head and Neck Cancer
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine if EMD 1201081 in combination with cetuximab is more efficient than cetuximab alone to control the cancer.
- Trial name
- NCT01040832
- Testing
- Cetuximab, EMD 1201081
- Where
- 35 sites in United States, Belgium and 6 more
- Volunteers
- 107 people
- Sponsor
- EMD Serono
Head and Neck Cancer
Everolimus Versus Placebo in Head and Neck Cancer
Primary: Two-year progression-free (tumor does not grow or spread) survival in subjects treated with everolimus versus placebo after definitive local therapy.
- Trial name
- NCT01111058
- Testing
- Everolimus (RAD 001)
- Where
- 17 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Chicago
Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This partially randomized phase II trial studies giving capecitabine and vorinostat in treating patients with head and neck cancer that has come back after previous treatment or that has spread to other areas in the body.
- Conditions
- Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT01267240
- Testing
- Capecitabine, Vorinostat
- Where
- 14 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel.
- Trial name
- NCT01285635
- Testing
- AT-101, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck…
- Trial name
- IMvoke010 (NCT03452137)
- Testing
- Atezolizumab
- Where
- 135 sites in United States, Australia and 21 more
- Volunteers
- 406 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer